Kwamesha Joseph

Assistant Editor https://www.endocrinologyadvisor.com

Kwamesha Joseph is an assistant editor for Endocrinology Advisor, Clinical Pain Advisor, Dermatology Advisor, and The Medical Bag brands of the Haymarket Medical Network. She holds a BA in english with minors in philosophy and African American studies from Fordham University. Prior to joining the network in 2018, Kwamesha interned with PRWeek's Operations and Audience Development team.

All articles by Kwamesha Joseph

Cardiovascular and Metabolic Disorders

Lurasidone Linked to Relatively Low Risk for Metabolic Syndrome in Bipolar Depression

Kwamesha Joseph

October 15, 2019

Investigators analyzed the potential metabolic effects of lurasidone in a sample of patients with bipolar I depression.

General Endocrinology

Prenatal Testosterone Exposure Reduces Socioeconomic Success, Fertility of Female Co-Twins

Kwamesha Joseph

April 10, 2019

Women exposed to a male co-twin in utero have decreased probability of fertility and socioeconomic success, according to study findings published in PNAS. For this study, researchers constructed a multivariable linear regression model to study the long-term effects of testosterone transfer in females who are opposite-sex co-twins. The model was designed using a longitudinal data…

ENDO 2019

Does Levothyroxine Increase Live-Birth Rates in Euthyroid Women With Thyroid Peroxidase Antibodies?

Kwamesha Joseph

March 25, 2019

Thyroid peroxidase antibodies are associated with an increased risk for miscarriage and preterm birth, even when thyroid function is normal.

Nurse taking a patient's blood sugar reading.

Diabetes

Glycemic Variability May Predict Incident Cardiovascular Disease, Mortality

Kwamesha Joseph

February 7, 2019

The researchers’ findings contribute to a growing body of evidence regarding the prognostic value of glycemic variability.

Diabetes

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization

Kwamesha Joseph

November 21, 2018

Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.

Type 2 Diabetes

Empagliflozin Effectively Reduces Risk for Heart Failure Hospitalization in T2D

Kwamesha Joseph

November 13, 2018

Approximately 50% of deaths in people with type 2 diabetes worldwide, and approximately two-thirds of deaths in people with type 2 diabetes in the US are caused by cardiovascular disease.